Navigation Links
Divine Corporation's Personal Lubricants Shown to Block Cancer-causing Viruses in a Study by the National Cancer Institute
Date:1/22/2008

An Independent Study by the National Cancer Institute Revealed Divine No. 9 and Divine No. 8 to be Highly Effective in Inhibiting Viruses that Cause

Cervical, Vaginal and Anal Cancers in vitro

ORLANDO, Fla., Jan. 22 /PRNewswire/ -- Divine Corporation announced today an unprecedented discovery in personal lubricants that promises to revolutionize the market. The National Cancer Institute's Laboratory of Cellular Oncology has completed a laboratory study of Divine Corporation's No. 9 and No. 8 personal lubricants and determined they are highly effective in blocking infection by certain strains of human papillomaviruses (HPVs) that have been proven to cause cervical, vaginal and anal cancers [1]. Divine No. 9 and Divine No. 8 personal lubricants now offer the possibility of HPV protection while at the same time enhancing the pleasure of intimate contact.

"We began by combining natural ingredients to create the best performing intimate lubricant on the market; one that would have unique and delightful play characteristics and feel great on your skin," said Stephanie Fresonke, President of Divine Corporation. "Thanks to the breakthrough work of the National Cancer Institute research team, Divine has now been shown to be an extremely potent human papillomavirus inhibitor in their laboratory studies. While clinical tests have not yet been performed, it is tremendously exciting to offer our customers the possibility to combine pleasure and protection in a single bottle."

Divine's unique formulations include an array of natural ingredients, most notably an extract from sea kelp called carrageenan. The National Cancer Institute study, "Carrageenan is a Potent Inhibitor of Papillomavirus Infection," has shown carrageenan to be an extremely effective topical microbicide for a broad range of sexually transmitted HPVs in vitro. The experiments compared a range of consumer products containing carrageenan. Divine No. 8 and Divine No. 9 pr
'/>"/>

SOURCE Divine Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Groundbreaking Study Proves Personalized Diet Based on Genetics Leads to Significant Advances in Long Term Weight Management and Blood Glucose Levels
2. Personalized Medicine - The Genomic Revolution in Cardiac Care
3. SCH 530348 (TRA), a Novel Investigational Antiplatelet Agent, Shown to Inhibit Platelet Aggregation in PCI Patients
4. RediClinic Offers Affordable New Plan Clinically Shown to Double a Persons Chance to Stop Smoking
5. Study Confirms That New Protocol Shortens the Time It Takes to Open Blocked Arteries for Heart Attack Patients
6. Sugammadex Trials Demonstrate Rapid Recovery from Profound Neuromuscular Blockade During General Anesthesia
7. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
8. Protalix BioTherapeutics Extends Research Agreement With Yissum Based on Promising Acetylcholinesterase Program Results in Animal Study
9. Northwestern Memorial Transplant Program Initiates New Study
10. Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent
11. CeloNova BioSciences Announces Positive Results from European Study of Embozene(TM) Microspheres for Treatment of Uterine Fibroids
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/8/2008)...ts for Spinal Cord, Other Nerve,Injuries -, PHILA...in that enables,nerve cells to communicate with ea...oping nervous system. Research into how that prote...ells may provide a basis for eventual,treatments f...ystem,including spinal cord injury., "This expan...
(Date:10/8/2008)...-ICR as Vaccine Adjuvant, SAN DIEGO, Oct. 8 /PRNe...poration (TSX: NVN) today presented positive data ...l-like Receptor 3 agonist, Poly IC-Poly,Arginine (...yon, France.,Study results demonstrated Poly-ICR t...like Receptor 3 (TLR3) pathway. Data showed that,P...
(Date:10/7/2008)... for detecting polyps that can be ...ct. 7 /- At the American College of,G...do (ACG 2008), renowned,gastroenterologist Douglas...tional clinical study that evaluated the efficacy ...at is designed to improve the ability,of physician...
(Date:10/7/2008)...all/ -- CEL-SCI Corporation,(NYSE: CVM ) announce...er,Agreement (MTA) with the National Institutes of... of Dr. Francesco M. Marincola, M.D., to,investiga...roenvironment,caused by CEL-SCI,s cancer drug Mult...s Disease and Immunogentics Section, Department of...
Breaking Medicine Technology:Protein Shown to Play a Key Role in Normal Development of Nervous System 2Protein Shown to Play a Key Role in Normal Development of Nervous System 3Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress 2Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress 3Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress 4Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress 5National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 2National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 3National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 4National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 5CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect 2CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect 3Mom You Rock 21 17145 1What You Dont Know Could Hurt You 17142 1What You Dont Know Could Hurt You 17142 2What You Dont Know Could Hurt You 17142 3Telik Presents Preclinical Data at 99th Annual Meeting of the American Association for Cancer Research 4690 1Telik Presents Preclinical Data at 99th Annual Meeting of the American Association for Cancer Research 4690 2Telik Presents Preclinical Data at 99th Annual Meeting of the American Association for Cancer Research 4690 3Breast Feeding While on Seizure Meds Doesnt Harm Babies 17141 1Breast Feeding While on Seizure Meds Doesnt Harm Babies 17141 2
...oupe Francophone du Myelome (IFM),Trial Presented ...ewswire-FirstCall/ --,Millennium Pharmaceuticals, ...n the comparative Phase III clinical trial evaluat...tiple myeloma (MM),patients. As induction therapy ...ADE based therapy produced a high complete remissi...
...Ablynx today announced positive,interim results fr...nt programme, ALX-0081, an anti-thrombotic treatme...e; therapeutic,Nanobody® targeting von Willebr...ombosis in patients with acute coronary,syndrome. ...ned to assess,safety, tolerability and pharmacokin...
Other Medicine Technology:Velcade (bortezomib) for Injection Based Induction Therapy,Delivered High Post-Transplant Complete Remission Rate, a Critical,Marker for Increased Overall Survival 2Velcade (bortezomib) for Injection Based Induction Therapy,Delivered High Post-Transplant Complete Remission Rate, a Critical,Marker for Increased Overall Survival 3Velcade (bortezomib) for Injection Based Induction Therapy,Delivered High Post-Transplant Complete Remission Rate, a Critical,Marker for Increased Overall Survival 4Velcade (bortezomib) for Injection Based Induction Therapy,Delivered High Post-Transplant Complete Remission Rate, a Critical,Marker for Increased Overall Survival 5Velcade (bortezomib) for Injection Based Induction Therapy,Delivered High Post-Transplant Complete Remission Rate, a Critical,Marker for Increased Overall Survival 6Ablynx Announces Interim Results of First Nanobody Phase I Study of,ALX-0081 (ANTI-VWF) 2
(Date:10/10/2008)...Coach Holly Warlick Teams Up with Legal and Medica...Ever Cancer and Careers Seminar in,Knoxville, KNO...ion of National,Breast Cancer Awareness Month, Can...e joined forces with YWCA Knoxville, The Wellness ...e Holly Warlick, University of Tennessee,women,s b...
(Date:10/10/2008)... The Healthcare Technology Ev... , Exton, PA (PRWEB) Sept...ey Chapters of the national Healthcare Information...forces to bring regional health information techno... conference entitled The Healthcare Technology Evo...
(Date:10/10/2008)...ston, MABoston Medical Center (BMC) has received a...l Institute on Aging (NIA) to fund the Boston Clau...BMC,s Pepper Center is one of only 11 Pepper Cente... Americans Independence Center Program was establi...enator from Florida. During his five decades of pu...
(Date:10/10/2008)...olecular CT adds metabolic information from PET to...gnostic imaging for maximized workflow ...ICH, Germany, Oct. 10 /PRNewswire/ -- Siemens Heal...duces molecular CT, a new concept in,integrated im...d is a,practical solution for today,s shrinking he...
Breaking Medicine News(10 mins):Health News:Local Experts Help Women Living and Working with Cancer Even the Score 2Health News:Local Experts Help Women Living and Working with Cancer Even the Score 3Health News:Local Experts Help Women Living and Working with Cancer Even the Score 4Health News:HIMSS New Jersey and Delaware Valley Chapters Sponsor Regional Conference 2Health News:Boston Medical Center receives $5.8m grant 2Health News:Siemens Shapes the Future of Integrated Diagnostic Imaging 2Health News:Siemens Shapes the Future of Integrated Diagnostic Imaging 3Health News:Siemens Shapes the Future of Integrated Diagnostic Imaging 4
...during and more often after their baby’s birth are... counseling services. // These were the findings ...it ‘Mind’. Depresssion in new mothers and soon-to...asingly frequent with at least one in six women ex...
... that about 4.1 million people in the US are infec...ate of infection was found to be 1.6%. The Hepatit...ontact with contaminated blood products. Drug user... the disease. It is found to be an important fact...
... website that advises about knee injuries without ...hospital. // A landmark in today’s world hooked ...e offers immediate expert advice on knee injuries ...ving them a chance to safely manage their symptoms...
...r for Military Health Research at King's College L...aq are suffering from health problems. // Hence th...ere had been an increase in ill health in soldiers...ng the mental and physical health of forces who ha...
Other Medicine News:
...oved ergonomics for today's exacting laboratory ro... rest and the large display windows enhance operat...so feature soft-touch tip ejection with power-boos...out for 0.2 - 50ul micro volume pipetting. For abs...
...ipettor for sub-microliter pipetting and beyond. O...usly adjustable. Features lPLUS, a direct-drive di...ngeable ejector buttons to fit large hands or tiny...ree different lengths. Air-displacement mechanism....
...oved ergonomics for today's exacting laboratory ro... rest and the large display windows enhance operat...so feature soft-touch tip ejection with power-boos...out for 0.2 - 50ul micro volume pipetting. For abs...
Research Series 2100 Adjustable-volume Pipette, 10-100 l, single-channel with adjustable-volume setting
Medicine Products: